194. Invest New Drugs. 2018 Jun 9. doi: 10.1007/s10637-018-0614-9. [Epub ahead ofprint]A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor ofsmoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.Ruiz-Borrego M(1), Jimenez B(2), Antolín S(3), García-Saenz JA(4), Corral J(1),Jerez Y(5), Trigo J(2), Urruticoechea A(6), Colom H(7), Gonzalo N(8), Muñoz C(8),Benito S(9), Caballero R(9), Bezares S(9), Carrasco E(9), Rojo F(10), MartínM(11).Author information: (1)Department of Medical Oncology, Hospital Universitario Virgen del Rocío,Sevilla, Spain.(2)Department of Medical Oncology, Hospital Clínico Universitario Virgen de laVictoria, IBIMA, Málaga, Spain.(3)Department of Medical Oncology, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain.(4)Department of Medical Oncology, IdISSC, CIBERONC-ISCIII, Hospital Clínico San Carlos, Madrid, Spain.(5)Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.(6)Department of Medical Oncology, Fundación Onkologikoa, San Sebastián, Spain.(7)Department of Biopharmaceutics and Pharmacokinetics, School of Pharmacy,University of Barcelona, Barcelona, Spain.(8)Department of Pharmacy, IDIBELL, Catalan Institute of Oncology, Hospital Durani Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.(9)GEICAM, Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid,Spain.(10)Department of Pathology, Instituto de Investigación Sanitaria FundaciónJiménez Díaz, Centro de Investigación Biomédica en Red de Oncología,CIBERONC-ISCIII, Madrid, Spain.(11)Department of Medical Oncology, Instituto de Investigación Sanitaria GregorioMarañón, Universidad Complutense, Centro de Investigación Biomédica en Red deOncología, CIBERONC-ISCIII, C/Dr. Esquerdo 46, 28009, Madrid, Spain.mmartin@geicam.org.Up-regulation of the Hedgehog (Hh) pathway is implicated in the genesis of a widerange of tumors including triple negative breast cancer (TNBC). Sonidegib is apotent and selective oral inhibitor of Smo, a key component of the Hh signalingpathway. We designed a phase I clinical study to explore the combination ofsonidegib plus docetaxel (fixed dose at 75 mg/m2) in advanced TNBC patients. The primary objective was to ascertain the combination's maximum tolerated dose andthe recommended phase II dose (RP2D), based on dose limiting toxicities (DLTs) inthe first 2 cycles. A standard "3 + 3" design was followed including three doselevels (DL) of sonidegib: 400 mg (DL1), 600 mg (DL2), and 800 mg (DL3). Twelvepatients were included. Sonidegib 800 mg orally q.d. plus docetaxel 75 mg/m2given intravenously on day 1 of 21-day cycles was established as the RP2D. NoDLTs were observed at any DL. The median number of administered cycles at DL3 was8 (range: 6 to 9). Grade 3 adverse events (AEs) at DL3 were neutropenia (66.7%), CPK increase (33.3%), leukopenia (33.3%), and paresthesia (33.3%), grade 4 AEswere not reported at this DL. At the RP2D, the combination showed antitumoractivity in three out of 10 patients with measurable disease. Median time toprogression for the overall study was 42.5 days (95% Confidence Interval:29-155), and 188 days at DL3. No drug-to-drug interactions between sonidegib and docetaxel were found in the PK assessment.TRIAL REGISTRATION: EudraCT studynumber: 2013-001750-96. Study GEICAM/2012-12.TRIAL REGISTRATION: EudraCT study number: 2013-001750-96. Study GEICAM/2012-12.ClinicalTrials.gov: NCT02027376.DOI: 10.1007/s10637-018-0614-9 PMID: 29948356 